Artiva Biotherapeutics (ARTV) Assets Average (2024 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Assets Average of $118.4 million for Q1 2026, down 40.9% year-over-year from $200.4 million in Q1 2025, and down 15.33% quarter-over-quarter from $139.9 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Assets Average (2024 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Assets Average for 3 consecutive years, with $118.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 40.9% year-over-year to $118.4 million; the TTM figure through Mar 2026 stood at $118.4 million (down 40.9% YoY), while the FY2025 annual figure was $170.3 million, up 8.21% from the prior year.
- Assets Average declined to $118.4 million in Q1 2026 per ARTV's latest filing, from $139.9 million in the prior quarter.
- Across five years, Assets Average topped out at $217.6 million in Q4 2024 and bottomed at $118.4 million in Q1 2026.
- Historically, Assets Average has averaged $166.7 million across 3 years, with a median of $159.1 million in 2025.
- Annual changes were most pronounced in 2025 — Assets Average gained 5.55% — and 2026, when it tumbled 40.9%.
- Artiva Biotherapeutics' Assets Average stood at $217.6 million in 2024, then slumped by 35.7% to $139.9 million in 2025, then retreated by 15.33% to $118.4 million in 2026.
- Business Quant data shows ARTV's Assets Average at $118.4 million in Q1 2026, $139.9 million in Q4 2025, and $159.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | 237.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 237.29 Mn |
| Mar 31, 2026 | 118.45 Mn |
| Dec 31, 2025 | 139.90 Mn |
| Sep 30, 2025 | 159.13 Mn |
| Jun 30, 2025 | 180.33 Mn |
| Mar 31, 2025 | 200.42 Mn |
| Dec 31, 2024 | 217.59 Mn |
| Sep 30, 2024 | 150.75 Mn |